跨界者OR接盘侠?核药、CGT、GLP-1,站满了中药大佬

华尔街见闻
Aug 08

很少有人会将一款在FDA获批的FIC药物与一家中国的传统中药龙头联系起来,但这种小概率事情实实在在地发生了。 8月7日,Jazz制药宣布FDA加速批准其口服活性小分子DRD2拮抗剂和ClpP激动剂Dordaviprone(多达维普酮)上市,用于治疗年龄≥1岁前线治疗进展的携带H3 K27M突变的弥漫性中线胶质瘤(DMG)患者。Jazz制药称,此为FDA批准的首个且唯一的治疗该适应证的药物。 伴随着...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10